Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY008211A tablet in primary IgA nephropathy (Phase II, randomized, double-blind, placebo-controlled)
CTR20244245Phase 2Active
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MY-008 in IgA nephropathy (IgAN), sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Started Dec 2024; status: active.
02
Drugs
MY-008
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20244245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244245.